A carbohydrate fraction, AIP1 from Artemisia iwayomogi suppresses pulmonary eosinophilia and Th2-type cytokine production in an ovalbumin-induced allergic asthma. Down-regulation of TNF-alpha expression in the lung.
Asthma is a chronic inflammatory disease of the airways characterized by reversible airway obstruction, airway hyperreactivity, and remodeling of the airways. The incidence of asthma is on the rise despite ongoing intensive asthma research. Artemisia iwayomogi, a member of the Compositae, is a perennial herb easily found around Korea and has been used as a traditional anti-inflammatory medicine in liver diseases. We investigated suppressive effects of AIP1, a water-soluble carbohydrate fraction from A. iwayomogi on ovalbumin-induced allergic asthma in BALB/c mice and studied the possible mechanisms of its anti-allergic action. AIP1 significantly reduced pulmonary eosinophilia and Th2 cytokine expression in the lungs as well as serum IgE levels. Flow cytometric analysis of lung-infiltrating cells showed that the surface levels of CD11c and MHC II in CD11c+MHC II+ cells, potent dendritic cells, decreased in animals treated with AIP1. Expression of TNF-alpha, one of several proinflammatory cytokines released into the airway during episodes of asthma, was down-regulated by AIP1 injection, suggesting that reduced expression of TNF-alpha could account for the suppression of pulmonary eosinophilia and Th2-type cytokine production by AIP1.
Lee
Jin-Ah
JA
Department of Biology, Changwon National University, Changwon, Kyungnam 641-773, South Korea.
Sung
Ha-Na
HN
Jeon
Chang-Hwan
CH
Gill
Byoung-Chul
BC
Oh
Gap-Soo
GS
Youn
Hyun-Joo
HJ
Park
Joo-Hung
JH
D000485:Allergens / Q000633:toxicity; D000818:Animals; D019306:Artemisia / Q000737:chemistry / Q000276:immunology*; D001249:Asthma / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D002241:Carbohydrates / Q000008:administration & dosage* / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000145:classification; D015536:Down-Regulation / Q000276:immunology*; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D008168:Lung / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000633:toxicity; D011657:Pulmonary Eosinophilia / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics
D000485:Allergens; D002241:Carbohydrates; D016207:Cytokines; D004365:Drugs, Chinese Herbal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D010047:Ovalbumin